[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE520708T1 - Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung - Google Patents

Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung

Info

Publication number
ATE520708T1
ATE520708T1 AT04749556T AT04749556T ATE520708T1 AT E520708 T1 ATE520708 T1 AT E520708T1 AT 04749556 T AT04749556 T AT 04749556T AT 04749556 T AT04749556 T AT 04749556T AT E520708 T1 ATE520708 T1 AT E520708T1
Authority
AT
Austria
Prior art keywords
nucleic acid
acid molecules
hiv
epitopes
encode
Prior art date
Application number
AT04749556T
Other languages
English (en)
Inventor
Renu Lal
Sherry Owen
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE520708T1 publication Critical patent/ATE520708T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/64Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645Dendrimers; Multiple antigen peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04749556T 2003-03-28 2004-03-26 Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung ATE520708T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45888003P 2003-03-28 2003-03-28
PCT/US2004/009767 WO2004085466A2 (en) 2003-03-28 2004-03-26 Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use

Publications (1)

Publication Number Publication Date
ATE520708T1 true ATE520708T1 (de) 2011-09-15

Family

ID=33098288

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04749556T ATE520708T1 (de) 2003-03-28 2004-03-26 Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung

Country Status (6)

Country Link
US (1) US7425611B2 (de)
EP (1) EP1608675B1 (de)
AT (1) ATE520708T1 (de)
AU (1) AU2004223855B8 (de)
CA (1) CA2519025A1 (de)
WO (1) WO2004085466A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
EP2222336A2 (de) * 2007-10-29 2010-09-01 GENimmune N.V. Verfahren und kits zur auslösung einer ctl-reaktion mit einem haupt-boost-schema
WO2011082422A2 (en) * 2010-01-04 2011-07-07 The Johns Hopkins University Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
WO2015002134A1 (ja) * 2013-07-02 2015-01-08 公益財団法人がん研究会 細胞性免疫誘導ワクチン
US10238741B2 (en) 2014-10-10 2019-03-26 The Trustees Of Columbia University In The City Of New York Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
WO2016057986A1 (en) * 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
CN113747915A (zh) * 2019-02-21 2021-12-03 森蒂瓦克斯公司 优化的疫苗组合物及其制备方法
EP3937976A4 (de) * 2019-03-12 2023-03-29 The General Hospital Corporation Stark vernetzte immunogenzusammensetzung
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
WO2021185851A1 (en) * 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
CR20230312A (es) 2021-01-14 2023-08-31 Gilead Sciences Inc Vacunas contra el vih y métodos de uso

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US6319503B1 (en) 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
CA2685270C (en) 1998-05-13 2014-07-29 Pharmexa Inc. Expression vectors for stimulating an immune response and methods of using the same
US20020182222A1 (en) 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
AU2150900A (en) 1998-11-16 2000-06-05 Board Of Regents, The University Of Texas System Hiv-specific t-cell induction
WO2001012216A1 (en) 1999-08-13 2001-02-22 Proteinix Company Heat shock fusion-based vaccine system
JP2003509035A (ja) 1999-09-16 2003-03-11 ザイコス インク. ポリエピトープポリペプチドをコードする核酸
EP1225907A4 (de) 1999-10-05 2005-06-22 Epimmune Inc Induktion zellulärer immunantworten gegen humanes immundefiziens virus-1 (hiv-1) mittels peptid- und nukleinsäureverbindungen
JP4805511B2 (ja) * 1999-12-23 2011-11-02 メディカル リサーチ カウンシル Hivに対する免疫応答における改善、または免疫応答に関する改善
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1130089A1 (de) * 2000-02-17 2001-09-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Membranvirus Ziel- und Fusion-subvirale Partikel enthaltende Zusammensetzung und diese enthaltende Impstoff
DE10010292A1 (de) 2000-03-02 2001-09-06 Zahnradfabrik Friedrichshafen Fahrzeugachse
ES2386884T3 (es) 2000-11-01 2012-09-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vectores de expresión capaces de inducir respuesta inmunomejorada y métodos para usarlos
US20030003440A1 (en) * 2001-03-14 2003-01-02 Lucia Lopalco Novel CCR5 epitope and antibodies against it
JP4588296B2 (ja) 2001-04-05 2010-11-24 ジョンズ・ホプキンス・ユニバーシティ キメラワクチン
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
KR20100063126A (ko) 2002-05-16 2010-06-10 버베리안 노딕 에이/에스 Hiv 조절/부속 단백질의 융합 단백질

Also Published As

Publication number Publication date
AU2004223855A1 (en) 2004-10-07
EP1608675A2 (de) 2005-12-28
AU2004223855B2 (en) 2010-06-17
AU2004223855B8 (en) 2011-03-17
EP1608675B1 (de) 2011-08-17
WO2004085466A3 (en) 2005-03-24
WO2004085466A2 (en) 2004-10-07
CA2519025A1 (en) 2004-10-07
WO2004085466A8 (en) 2005-10-13
US7425611B2 (en) 2008-09-16
US20060216305A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
AR129651A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CY1122576T1 (el) Ανθρωπινα αντισωματα που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (leg-3), και χρησεις εξ' αυτων
EA202091710A1 (ru) Антитела против cd73 и способы их применения
NO20064059L (no) Albumin fusjonsproteiner
EA202092735A1 (ru) Антагонизирующее cd73 антитело
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
ATE520708T1 (de) Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
ATE533782T1 (de) Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür
BRPI1008692B8 (pt) anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
MX2009002816A (es) Proteinas de fusion de albumina.
TNSN08064A1 (en) Albumin fusion proteins
BRPI0507489A (pt) anticorpos humanos de anti-cd38 e para os seus usos
EA200702093A1 (ru) Антитела-миметики glp-1 человека, композиции, способы и их применение
NO20091387L (no) Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EA201491171A1 (ru) Вещества, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения
NO20062044L (no) Piscirickettsia salmonis-antigener og anvendelse derav
DK2054431T3 (da) Konformere af bakterielle adhæsiner
Leblanc et al. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
AR041086A1 (es) Vacuna
FR2911608B1 (fr) Nouvelles compositions vaccinales anti paludique et ses utilisations.
Tinker et al. Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery
WO2018102774A8 (en) Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties